Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664
Lucas A, Sinha A, Fowler KB, Mladsi D, Barnett C, Samant S, Gibson L. A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States. Cost Eff Resour Alloc. 2019 Oct 3;17(1):21. doi: 10.1186/s12962-019-0189-0
Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Gitlin M, Robbins S. Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom. Bone. 2012 Sep 1;51(3):324-31.
Zimovetz EA, Wolowacz SE, Classi PM, Birt J. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost Eff Resour Alloc. 2012 Feb 1;10(1):1.
Kiel DP, Grazette L, Siddhanti S, Daizadeh N, Wang A, Anthony MS, Christiansen C. Effect of denosumab on 3-year progression of aortic calcification in postmenopausal women with osteoporosis at high risk of cardiovascular events. Poster presented at the 37th European Symposium on Calcified Tissues Conference; June 2010. Glasgow, Scotland. [abstract] Bone. 2010 Jun; 47(Suppl 1):S69. doi: 10.1016/j.bone.2010.04.134